| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.25 | 3e-14 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 7e-11 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-10 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.098 | 0.0003 |